Aspartame effect in sickle cell anemia

Clinical Pharmacology and Therapeutics

Volumn 69, Issue 5, 2001, Pages 346-355

  Manion, Carl V ^a,b   Howard, Jessica ^a   Ogle, Brandi ^a   Parkhurst, Joan ^a   Edmundson, Allen ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTAME; BENCE JONES PROTEIN; HEMOGLOBIN S; PHENYLALANINE; SODIUM METABISULFITE;

ADOLESCENT; ADULT; ARTICLE; BINDING SITE; CELL COUNT; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG PROTEIN BINDING; FEMALE; HUMAN; HYDROPHOBICITY; MALE; MICROPHOTOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SICKLE CELL; SICKLE CELL ANEMIA;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; ASPARTAME; BLOOD; BLOOD VISCOSITY; CHILD; CHILD, PRESCHOOL; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED;

EID: 0035338740     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2001.115141     Document Type: Article

References (42)

1. Rodgers DW, Crepeau RH, Edelstein SJ. Pairings and polarities of the 14 strands in sickle cell hemoglobin fibers. Proc Natl Acad Sci USA 1987;84:6157-61.
2. Eaton WA, Hofrichter J. Sickle cell hemoglobin polymerization. Adv Protein Chem 1990;40:63-279.
3. Charache S, Davies S. Teaching both the management and the molecular biology of sickle cell disease. Acad Med 1991;66:748-9.
4. Pauling L, Itano HA, Singer SJ, Wells IC. Sickle cell anemia, a molecular disease. Science 1949;110:543-8.
5. Ingram VM. A specific chemical difference between the globins of normal human and sickle-cell anemia hemoglobin. Nature 1956;178:792-4.
6. Padlan EA, Love WE. Refined crystal structure of deoxyhemoglobin S; II: Molecular interactions in the crystal. J Biol Chem 1985;260:8280-91.
7. Stryer L. Portrait of an allosteric protein. In: Stryer L. Biochemistry. 4th Ed. New York: WH Freeman; 1995. p. 147-80.
8. Dickerson RE, Geis L. Hemoglobin: Structure, Function, Evolution, and Pathology. 1st Ed. Menlo Park: Benjamin/Cummings; 1983.
9. Steinberg MMD. Management of sickle cell disease. N Engl J Med 1999;340:1021-30.
10. Mbonda E, Thuret I, Pinsard N. Ischemie cerebrovascular accidents in homozygous sickle cell anemia: Two case reports. Ann Pediatr (Paris) 1993;40:23-7.
11. Alleyne J, Thomas VJ. The management of sickle cell crisis pain as experienced by patients and their carets. J Adv Nurs 1994;19:725-32.
12. Ferster A, Bujan W, Corazza F, Devalck C, Fondu P, Toppet M, et al. Bone marrow transplantation corrects the splenic reticuloendothelial dysfunction in sickle cell anemia. Blood 1993;81:1102-5.
13. Chakrabarty A, Upadhyay J, Dhabuwala CB, SArnaik S, Perlmutter AD, Connor JP. Priapism associated with sickle cell hemoglobinopathy in children: Long-term effects on potency. J Urol 1996;155:1419-23.
14. Dreyer ZE. Chest infections and syndromes in sickle cell disease of childhood. Semin Respir Infect 1996;11: 163-72.
15. Al-Salem All, Qaisaruddin S, AI Jam'a A, Al-Kalaf J, El-Bashier AM. Splenic abscess and sickle cell disease. Am J Hematol 1998;58:100-4.
16. Edmundson AB, Manion CV. Treatment of osteoarthritis with aspartame. Clin Pharmacol Ther 1998;63: 580-93.
17. Anchin JM, Linthicum DS. Molecular and computational techniques for modeling antibody combining sites. J Clin Immunoassay 1992;15:35-41.
18. Schechter AN. Stereospecific inhibitors of the gelation of sickle hemoglobin. Hemoglobin 1980;4:335-45.
19. Noguchi CT, Torchia DA, Schechter AN. Determination of sickle hemoglobin polymer in SS and AS erythrocytes. Blood Cells 1982;8:225-35.
20. Noguchi CT, Schechter AN. Sickle hemoglobin polymerization in solution and in cells. Annu Rev Biophys Biophys Chem 1985;14:239-63.
21. Kumpati J. Liposome-loaded phenylalanine or tryptophan as sickling inhibitor: A possible therapy for sickle cell disease. Biochem Med Metab Biol 1987;38:170-81.
22. Franklin IM, Cotter RI, Cheetham RC, Pardon JF, Hale AJ, Huehns ER. A potent new dipeptide inhibitor sickling and haemoglobin S gelation. Eur J Biochem 1983;136:209-14.
23. Ramsland PA, Movafagh BF, Reichlin M, Edmundson AB. Interference of rheumatoid factor activity by aspartame, a dipeptide methyl ester. J Mol Recognit 1999; 12:249-57.
24. Khachaturian ZS, Cotman CW, Pettegrew JW. Calcium, membranes, aging, and alzheimer's disease. Ann NY Acad Sci 1989;568:58-9.
25. Daland GA, Castle WB. A simple and rapid method for demonstrating sickling of the red blood cells: The use of reducing agents. J Lab Clin Med 1948;33:1082-8.
26. Nelson DA. Erythrocytic disorders. In: Henry JB, ed. Todd-Sanford-Davidsohn Clinical Diagnosis by Laboratory Methods; Vol 1. 16th ed. Philadelphia: WB Saunders; 1979. p. 1020.
27. Wright DJ, Jenkins DE. Simplified method for estimation of serum and plasma viscosity in multiple myeloma and related disorders. Blood 1970;36:516-22.
28. Pirofsky B. The determination of blood viscosity in man by a method based on Poiseuilles's law. J Clin Invest 1953;32:292-8.
29. Ranney HM. Sickle Cell Disease: Blood. 1972;39:433-9.
30. Aluoch Jr. [The treatment of sickle cell disease]. Ned Tijdschr Geneeskd 1984;128:1187-90.
31. Serjeant GR. Chronic transfusion programmes in sickle cell disease: Problem or panacea? [see comments]. Br J Haematol 1997;97:253-5.
32. Scott-Conner CE, Brunson CD. The pathophysiology of the sickle hemoglobinopathies and implications for perioperative management. Am J Surg 1994;168:268-74.
33. Charache S. Experimental therapy. Hematol Oncol Clin North Am 1996;10:1373-82.
34. Olivieri NE, Vichinsky EP. Hydroxyurea in children with sickle cell disease: Impact on splenic function and compliance with therapy. J Pediatr Hematol Oncol 1998;20: 26-31.
35. Lane PA. Sickle cell disease. Pediatr Clin North Am 1996;43:639-64.
36. Pollack CV Jr, Sanders DY, Severance HW Jr. Emergency department analgesia without narcotics for adults with acute sickle cell pain crisis: Case reports and review of crisis management. J Emerg Med 1991;9:445-52.
37. Comer GM, Ozick LA, Sachdev RK, Kumar S, Taunk JL, Smith JA, et al. Transfusion-related chronic liver disease in sickle cell anemia. Am J Gastroenterol 1991;86:1232-4.
38. Campbell LC, Von Burton G, Holcombe RF. Transfusion therapy in sickle cell disease patients: Methods and acute indications. J La State Med Soc 1993;145:515-21.
39. Collins AF, Fassos FF, STobie S, Lewis N, Shaw D, Fry M, et al. Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease. Blood 1994;83:2329-33.
40. Briehl RW. Rheology of hemoglobin S gels: Possible correlation with impaired microvascular circulation. Am J Pediatr Hematol Oncol 1983;5:390-8.
41. Bessis M, Feo C, Jones E. Quantitation of red cell deformability during progressive deoxygenation and oxygenation in sickling disorders (the use of an automated Ektacytometer). Blood Cells 1982;8:17-28.
42. Chien S, King RG, Kaperonis AA, Usami S. Viscoelastic properties of sickle cells and hemoglobin. Blood Cells 1982;8:53-64.